Efficacy and safety of low-frequency repetitive transcranial magnetic stimulation in post-stroke depression: A fNIRS pilot study.

Psychiatry ResMay 26, 2026 (epub)
Clinical ResearchPsychiatry

Yi Fan, Yujie Zhong, Anqi Yu et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy and safety of low-frequency repetitive transcranial magnetic stimulation (LF-rTMS) on the right dorsolateral prefrontal cortex in 28 patients with post-stroke depression. Results indicated that HAMD scores decreased significantly in the rTMS group compared to controls (p < 0.05), suggesting LF-rTMS may effectively alleviate depressive symptoms in this population.

Key findings

  • HAMD scores decreased significantly more in the rTMS group compared to controls (p < 0.05).
  • Significant improvements were observed in HAMA, NIHSS, and Barthel Index scores in the rTMS group (p < 0.05).
  • fNIRS showed increased oxyhemoglobin and decreased deoxyhemoglobin in specific channels after rTMS (p < 0.05).

Why it matters

Post-stroke depression is a common and debilitating condition that can hinder recovery. This study suggests that LF-rTMS may provide a safe and effective adjunctive treatment option, potentially improving patient outcomes and quality of life.

Source

PubMed · PMID 42217404

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.